Icotrokinra results show potential to set a new standard of treatment in plaque psoriasis

Standout combination of complete skin clearance and favorable safety profile in a once daily pill could shift treatment paradigmNearly half of patients with moderate-to-severe plaque psoriasis (PsO) treated with investigational icotrokinra achieved completely clear skin (IGA 0) at Week 24 in Phase 3 ICONIC-LEADTopline results from Phase 3 ICONIC-ADVANCE 1&2 studies show icotrokinra achieved co-primary endpoints and showed superiority to deucravacitinib in moderate-to-severe plaque PsO These results pave the ...